Publications by authors named "K Mourier"

Introduction: Spine surgery is one of the specialties with the highest medicolegal risk, with a legal action initiated every 17 months per practitioner. One of the most dreaded complications is an epidural hematoma with postoperative deficit. The treatment of this complication is still being debated.

View Article and Find Full Text PDF

Background: Population aging raises questions about extending treatment indications in elderly patients with aneurysmal subarachnoid hemorrhage (aSAH). We therefore assessed functional status 1 year after treatment.

Methods: This study involved 310 patients, aged over 70 years, with ruptured brain aneurysm, enrolled between 2008 and 2014 in a prospective multicentre trial (FASHE study: NCT00692744) but considered unsuitable for randomisation and therefore analysed in the observational arms of the study: endovascular occlusion (EV), microsurgical exclusion (MS) and conservative treatment.

View Article and Find Full Text PDF

Background: Current aging of the population with good physiological status and the increasing incidence of subarachnoid hemorrhage (SAH) in elderly patients has enhanced the benefit of treatment in terms of independence and long-term quality of life (QoL).

Methods: From November 1, 2008 to October 30, 2012, 351 patients aged 70 years or older with aneurysmal SAH underwent adapted treatment: endovascular coiling (EV) for 228 (65%) patients, microsurgical clipping (MS) for 75 (29.3%) or conservative treatment for 48 (13.

View Article and Find Full Text PDF

Objective: To evaluate modifications in static spinal status after posterior decompression surgery without fusion in patients with symptomatic central canal stenosis.

Methods: From November 2014 to May 2016, 72 patients who underwent isolated decompression for lumbar spinal stenosis were enrolled prospectively in this single-center study. All of the patients had lateral full-body x-ray scans with the EOS system (EOS Imaging, Paris, France) before surgery and after 12 months of follow-up.

View Article and Find Full Text PDF
Article Synopsis
  • * A study found that only patients with a high baseline neutrophil count (≥6000/mm3) experienced significant benefits from bevacizumab, with survival times of 17.3 months versus 8.8 months for those without high counts.
  • * Further validation from additional trials indicated that high expression of the CSF3 gene, linked to neutrophil growth, also predicted better outcomes for patients on bevacizumab, confirming its status as a potential biomarker for treatment effectiveness.
View Article and Find Full Text PDF